DoctorWoldesellassie Bezabhe

Senior Lecturer in Medication Safety

Pharmacy

  • Senior Lecturer in Medication Safety
    Pharmacy
  • 362268312 (Work)
  • School of Pharmacy and Pharmacology, Pharmacy, 4007, Level 04 Pharmacy Building, Sandy Bay Campus, TAS

FUNDED PROJECTS

  • GRANT
    Does the improved atrial fibrillation management during hospitalisation persist and improve clinical outcomes?
    1 Aug 2026 - 31 Jan 2028
    People funded by this grant:
    • Gelaw B,
    • Bezabhe W,
    • Dwyer N,
    • Peterson G,
    • Mirkazemi C
    Project Total: $7,000; Atrial fibrillation (AF) affects nearly 500,000 Australians, with prevalence expected to double within two decades due to population ageing, improved survival from AF-associated risk factors, and enhanced detection. AF increases the risk of ischaemic stroke fivefold, and approximately one-third of all strokes are attributable to AF. These events are disproportionately severemore likely to be fatal, recurrent, and economically burdensomecosting the Australian healthcare system an estimated $5 billion annually. Oral anticoagulants (OACs) reduce stroke risk by 64%, yet real-world persistence remains suboptimal. Our recent study at the Royal Hobart Hospital (RHH), published in the European Journal of Clinical Investigation and supported by the 2023 Royal Hobart Research Foundation (RHHRF) Incubator Grant, demonstrated that multidisciplinary care improved guideline-concordant OAC prescribing from 53.8% at admission to 73.8% at discharge. The studys clinical relevance was further underscored in an invited editorial by Boriani et al, a member of the European Society of Cardiology Guidelines Committee. Despite gains in initiation, continuity of OAC therapy post-discharge, incidence of cardiovascular-related rehospitalisation and stroke, and the implementation of integrated AF management remain unexamined in Tasmania and nationally. This study will generate real-world evidence across the following areas: (i) rates and factors of OAC discontinuation at 12 months; (ii) incidence and drivers of cardiovascular-related rehospitalisation and stroke; and (iii) adherence to the ABC pathway (Avoid stroke, Better symptom control, Cardiovascular/comorbidity management) and its impact on clinical outcomes. By addressing these gaps, the study directly supports Australias national health priority of cardiovascular disease by targeting AF and its common comorbidities. These efforts align with national strategies to reduce stroke risk and improve chronic disease management across high-burden populations. Given that OACs are among the most clinically impactful yet high-risk therapies, enhancing their safe and sustained use is a national imperative. Findings will strengthen evidence-based practice, empower multidisciplinary teams, and promote holistic AF care that extends beyond stroke preventionultimately improving patient outcomes in Tasmania and across Australia. Funded by: Royal Hobart Hospital Research Foundation - Research Project Grant ($7,000); University of Tasmania.
  • GRANT
    Optimising Oral Anticoagulant Use in Hospitlised Patients with Atrial Fibrillation: An Opportunity Enhancement Intervention.
    1 Jan 2025 - 30 Dec 2026
    People funded by this grant:
    • Bezabhe W,
    • Peterson G,
    • Dwyer N,
    • Mirkazemi C,
    • Black DA
    Project Total: $25,000; Appropriate use of oral anticoagulants (OACs) reduces the risk of stroke and death by 64% and 25%, respectively. In our previous study that compared OAC prescribing at admission (community) and discharge (hospital), we confirmed that, in routine care, the RHH team improved the guideline appropriateness of OAC use in patients with atrial fibrillation. However, half of the patients with guideline-inappropriate OAC prescribing at admission were discharged without correction. The efficiency of correcting inappropriate OAC use varied significantly across RHH admission wards. An intervention that enhances the likelihood of the RHH care team to correct inappropriate OAC use is required. Funded by: Royal Hobart Hospital Research Foundation - Grant-Project ($25,000); University of Tasmania.
  • GRANT
    Use of Cardiovascular Disease Preventive Medications in Tasmanian Cancer Survivors
    1 Jan 2025 - 31 Dec 2025
    People funded by this grant:
    • Bezabhe W,
    • Peterson G,
    • Black DA,
    • Mirkazemi C,
    • Dwyer N
    Project Total: $10,000; The number of Tasmanians living with cancer is estimated to be over 30,000 and is increasing. A study using the Tasmanian Cancer Registry data found that heart and blood vessel disorders known as cardiovascular disease (CVD) are the leading causes of non-cancer death in Tasmanians with cancer. Over a quarter of all deaths and more than half of all non-cancer deaths are caused by CVD. However, no study examined the use of CVD preventive medications in Tasmanian cancer survivors. This study aims to investigate CVD preventive medication use following acute coronary syndrome admission in Tasmanian cancer survivors. Funded by: Royal Hobart Hospital Research Foundation - Grant-Incubator ($10,000); University of Tasmania.
  • GRANT
    From Reduction to Optimisation: Integrating an Alert System for Anticholinergic Medication in the Elderly
    1 Jan 2024 - 30 Sep 2026
    People funded by this grant:
    • Salahudeen M,
    • Peterson G,
    • Adamczewski B,
    • Wilson A,
    • Bayer G
    Project Total: $24,944; The safe and quality use of medicines is a new National Health Priority Area, with significant health consequences, particularly for older people. This innovative project will implement and evaluate a sticker alert system in the patients progress notes to optimise anticholinergic medication therapy to reduce the risk of adverse outcomes. The project also aims to modify the existing anticholinergic medications rating score (high=3, moderate=2, low=1) for the Australian context through a modified Delphi process. Funded by: Royal Hobart Hospital Research Foundation - Grant-Project ($24,944); University of Tasmania.
  • GRANT
    Hospitalisation as an opportunity to optimise anticoagulant treatment in patients with atrial fibrillation
    1 Jan 2023 - 30 Jun 2024
    People funded by this grant:
    • Bezabhe W,
    • Peterson G,
    • Radford J,
    • Boland C,
    • Salahudeen M
    Project Total: $9,985; Our recent studies indicate that many community-based patients with atrial fibrillation and a high stroke risk still do not receive the recommended anticoagulant therapy. This study will examine anticoagulant use in patients with atrial fibrillation upon admission and discharge and determine whether hospitalisation represents an opportunity to improve the quality of care. Funded by: Royal Hobart Hospital Research Foundation - Grant-Incubator ($9,985); University of Tasmania.
  • GRANT
    Intervention to lessen anticholinergic drug burden in hospitalised older adults
    1 Jan 2022 - 30 Jun 2023
    People funded by this grant:
    • Salahudeen M,
    • Peterson G,
    • Adamczewski B,
    • Hoyle D,
    • McKenzie D
    Project Total: $9,996; Drugs with anticholinergic properties carry significant risks in older people, including extended hospital admissions, falls, dementia and increased mortality. However, the pattern of anticholinergic drug prescribing in Tasmania is not yet known. This study will investigate the effectiveness of an educational intervention to improve prescribing of anticholinergic-type drugs. Funded by: Royal Hobart Hospital Research Foundation - Grant-Incubator ($9,996); University of Tasmania.